MLLT3 sustains human HSC self-renewal and engraftment
The use of hematopoietic stem cells (HSC) for treating hematopoietic malignancies and genetic disorders is limited by availability of HLA-matched donors. If HSC could be expanded in culture or derived from pluripotent stem cells (PSCs), the number of patients and the spectrum of treatable diseases would greatly increase. To uncover the genetic network that promotes HSC self-renewal, we identified genes whose expression is enriched in self-renewing human hematopoietic stem and progenitor cells (HSPC) in fetal liver (FL), and that are down-regulated in cultured HSPC.
Source: Experimental Hematology - Category: Hematology Authors: Vincenzo Calvanese, Andrew T. Nguyen, Timothy Bolan, Zoran Galic, Hanna Mikkola Source Type: research
More News: Cancer & Oncology | Genetics | Hematology | Liver | Stem Cell Therapy | Stem Cells | Urology & Nephrology